# Rinvoq

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rinvoq
Canonical HTML page: https://getbiobrief.com/entity/rinvoq

## Recent coverage (2 stories)

### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print
2026-07-28 01:06:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth

### RBC Capital Initiates AbbVie Coverage with Outperform Rating
2026-02-27 14:46:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.